Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 49Neoplasms 36Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 25Polycystic Ovary Syndrome 16Pain 15Keratosis, Actinic 14Leukemia 12Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Lung Neoplasms 10Leiomyoma 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Carcinoma, Renal Cell 9Brain Neoplasms 9Neuroendocrine Tumors 8Arthritis, Rheumatoid 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Kidney Neoplasms 7Head and Neck Neoplasms 7Colonic Neoplasms 7Cancer Pain 7Multiple Myeloma 6Lymphoma 6Liver Neoplasms 6

Interventions

soybean oil, phospholipid emulsion 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Has results × Pena Shokeir syndrome, type 1 × Clear all
NCT04555044 2023-12-27

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Baxter Healthcare Corporation

Phase 4 Completed
101 enrolled 29 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

NCT02476994 2021-07-21

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Baxter Healthcare Corporation

Phase 4 Terminated
1 enrolled 4 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡